Home » Management

Management

Boris Umylny, Ph. D., CEO
Dr. Umylny has an undergraduate degree in Computer Science from Columbia University, and a PhD in Cell and Molecular Biology from the University of Hawaii. Professionally, Dr. Umylny has more than twenty years of hands-on expertise developing, selling, integrating, using, and maintaining complex enterprise software – initially for financial firms, and more recently (with Lumenogix) – for genomic and related science research.

In 1992 Dr. Umylny co-founded Fusion Systems Japan, a Tokyo-based consulting and software development company specializing in financial systems development and integration for which he served as Vice President until selling the firm via an M&A transaction in 1999. In this capacity, Dr. Umylny was responsible for all development and deployment of electronic trading and order execution platforms where he also oversaw and managed integrations for most of the major brokerage firms operating in Asia, including Jardine Fleming, Deutsche Bank, Morgan Stanley, Paribas, First Boston, Credit Suisse, UBS, and Hitachi among many others.

In 2001 Dr. Umylny enrolled in a PhD program at the University of Hawaii and later received his degree in December of 2006. He founded Japan Bioinformatics KK in December 2007 to develop Simbiot to provide an enterprise grade SaaS platform capable of serving the worldwide academic and commercial genomic research markets for storing and analyzing genomic (specifically NGS) data. From June 2011 to July 2012, concurrent with running Japan Bioinformatics, Dr. Umylny also served as CIO of GENEWIZ (which services approximately half of the US market for Sanger sequencing) where he was responsible for all aspects of development and integration of their enterprise wide IT platform. In June, 2013 Dr. Umylny co-founded Lumenogix, which acquired the assets of Japan Bioinformatics, and which took over and assumed all operations of the predecessor company.

Callum J. Bell, Ph.D., CSO
Dr. Bell brings 25 years of experience in genetics, genomics and bioinformatics to Lumenogix, with research, development and management experience spanning animal, plant and microbial kingdoms. He graduated from the University of Edinburgh with a Ph.D. in Plant Genetics, focusing on Arabidopsis before the plant became popular as a model for genetics, and followed this up with postdoctoral studies in which he created the first Arabidopsis genetic map based on molecular markers. Subsequently, he transitioned into human genetics and genomics, leading the program at the Children’s Hospital of Philadelphia to map human chromosome 22 in one of the first centers comprising the Human Genome Project. Dr. Bell moved to the biotechnology industry in 1996, running an interdisciplinary team involved with mapping Type 2 diabetes and obesity genes at Sequana Therapeutics. Since then he has had deep involvement in bioinformatics and human genetics, at the women’s health company Emergen in the early 2000s, and joining NCGR in 2008 to work on a ground-breaking screening test to identify carriers of rare childhood genetic diseases. He has significant experience working in technology startups, having received two Phase 2 SBIR awards for software and algorithm development at Seirad Inc. His experience gives him an unique view of bioinformatics products as both a consumer and producer. Dr. Bell is CSO in Lumenogix.

John Speck, M.B.A., C.P.A., CFO
Mr. Speck is a CPA and has an MBA from the University of Texas at San Antonio. In 1984 Mr. Speck joined the Southwest Foundation for Biomedical Research (SFBR) in San Antonio, where he stayed until 2006. Mr. Speck held two leadership roles at SFBR. He was the Controller from 1984 through 1989 and the Treasurer from 1989 through 2006.

In June 2007, Mr. Speck joined the National Center for Genome Resources as the Chief Financial Officer and Vice President for Administration. His duties included directing the administrative support services, administering the annual budget, developing public relations and fundraising programs, working with the Board and its committees; and working with the CEO to develop strategic plans.

Ian Dillon,  Director Business Development
Ian Dillon brings with him an advanced degree in Theoretical Chemistry and over 20 years of sales, marketing and business management experience. His primary career focus has been on High Performance Computing and cloud technologies for Scientific, Enterprise and Cyber Security markets. Ian’s collaborative sales has led to sustained partnerships with organizations like Cray, Cisco, Google, Microsoft and numerous national laboratories, including Los Alamos and Sandia.